Table 2:
HR | 95% CI | aHR | 95% CI | |
---|---|---|---|---|
Among PWH and PWoH (N=109,599) a | ||||
HIV status | ||||
PWoH | 1.00 | -- | 1.00 | -- |
PWH | 1.43 | 1.30, 1.58 | 1.41 | 1.28, 1.56 |
Among PWH (N=25,478) b | ||||
Sex | ||||
Male | 1.00 | 1.00 | ||
Female | 0.98 | 0.70, 1.37 | 0.96 | 0.67, 1.36 |
Ethnicity and Race | ||||
Non-Hispanic white | 1.00 | 1.00 | ||
Non-Hispanic Black/African | 1.08 | 0.89, 1.31 | 1.04 | 0.85, 1.27 |
American | ||||
Hispanic | 1.32 | 1.02, 1.70 | 1.05 | 0.81, 1.37 |
Non-Hispanic Asian | 1.32 | 0.84, 2.07 | 1.02 | 0.64, 1.62 |
Other | 0.98 | 0.59, 1.63 | 0.91 | 0.55, 1.52 |
Unknown | 1.31 | 0.58, 2.95 | 1.01 | 0.44, 2.29 |
Age (years) | ||||
18–24 | 3.21 | 1.31, 7.86 | 2.94 | 1.19, 7.24 |
25–34 | 1.09 | 0.74, 1.60 | 0.98 | 0.66, 1.46 |
35–44 | 1.06 | 0.79, 1.42 | 1.00 | 0.74, 1.34 |
45–54 | 1.00 | 1.00 | ||
55–64 | 0.73 | 0.58, 0.93 | 0.76 | 0.60, 0.96 |
65–74 | 0.63 | 0.49, 0.81 | 0.73 | 0.56, 0.95 |
75+ | 0.63 | 0.44, 0.91 | 0.76 | 0.52, 1.11 |
Primary vaccination series type | ||||
Moderna | 0.61 | 0.51, 0.74 | 0.61 | 0.51, 0.74 |
Pfizer | 1.00 | 1.00 | ||
J&J | 1.56 | 1.17, 2.09 | 1.35 | 1.01, 1.82 |
COVID-19 prior to fully vaccinated | ||||
No | 1.00 | 1.00 | ||
Yes | 3.08 | 2.49, 3.83 | 2.87 | 2.30, 3.56 |
Calendar period | ||||
Jan – March | 1.57 | 0.92, 2.69 | 1.68 | 0.99, 2.88 |
April – June | 1.00 | 1.00 | ||
July – Sept | 3.22 | 2.34, 4.44 | 2.92 | 2.12, 4.03 |
HIV RNA | ||||
Unsuppressed (≥50 copies/mL) | 1.00 | 1.00 | ||
Suppressed (<50 copies/mL) | 0.97 | 0.75, 1.26 | 1.04 | 0.80, 1.35 |
CD4 count at fully vaccinated (cells/mm3) | ||||
<200 | 1.00 | 1.00 | ||
200–349 | 1.03 | 0.71, 1.50 | 1.02 | 0.70, 1.48 |
350–499 | 0.84 | 0.59, 1.19 | 0.83 | 0.59, 1.19 |
≥500 | 0.79 | 0.59, 1.07 | 0.74 | 0.54, 1.01 |
Abbreviations: HR=crude hazard ratio. aHR=adjusted hazard ratio. 95% CI=95% confidence interval.
Adjusted for age, sex, race and ethnicity, primary vaccination series type, COVID-19 prior to fully vaccinated, 3-month calendar period, an interaction of COVID-19 prior to fully vaccinated and 3-month calendar period, and cohort.
N=6,362 (20% of all PWH) were excluded due to missing CD4 or HIV RNA measurements. Adjusted for the covariates in the table and cohort.